PRIME Dry Spell Ends As EMA Takes On Eye Disease Gene Therapy

The first designation of 2018 under the European Medicines Agency’s PRIME scheme has gone to an advanced therapy for patients with the severe eye disorder, achromatopsia. In the meantime, most PRIME applications are still getting rejected.